Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters

BookmarkUs

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy